ojrdrtОнкологический журнал: лучевая диагностика, лучевая терапияJournal of oncology: diagnostic radiology and radiotherapy2587-75932713-167XНЕКОММЕРЧЕСКОЕ ПАРТНЕРСТВО «ОБЩЕСТВО ИНТЕРВЕНЦИОННЫХ ОНКОРАДИОЛОГОВ»10.37174/2587-7593-2020-3-3-44-53ojrdrt-130Research ArticleЛУЧЕВАЯ ДИАГНОСТИКАDIAGNOSTIC RADIOLOGYЛучевая диагностика иммунотерапевтических осложненийRadiological Imaging of Adverse Events to Immunotherapyhttps://orcid.org/0000-0002-6845-5613ЗябловаЕ. И.ZyablovaE. I.

Зяблова Елена Игоревна — заведующий рентгеновским отделением, НИИ Краевая клиническая больница № 1 им. проф. С.В. Очаповского, кандидат медицинских наук.350086, Краснодар, ул. 1 Мая, 167.SPIN-код: 1618-0141

167, 1st May, Krasnodar, 350086.

elenazyablova@inbox.ruhttps://orcid.org/0000-0002-8328-6926НефедоваЛ. Н.NefedovaL. N.

Нефедова Любовь Николаевна — врач-онколог отделения онкологии, ГНИИ Краевая клиническая больница № 1 им. проф. С.В. Очаповского.350086, Краснодар, ул. 1 Мая, 167.

167, 1st May, Krasnodar, 350086.

lnefedova@mail.ruhttps://orcid.org/0000-0003-0572-1395ПорхановВ. А.PorkhanovV. A.

Порханов Владимир Алексеевич — главный врач, НИИ Краевая клиническая больница № 1 им. проф. С.В. Очаповского, доктор медицинских наук, профессор, академик РАН.350086, Краснодар, ул. 1 Мая, 167.

167, 1st May, Krasnodar, 350086.

vladimirporhanov@mail.ruНИИ Краевая клиническая больница № 1 им. проф. С.В. ОчаповскогоРоссияScientific Research Institute — Ochapovsky Regional Clinic Hospital No. 1Russian Federation202030092020334453Copyright © Зяблова Е.И., Нефедова Л.Н., Порханов В.А., 20202020Зяблова Е.И., Нефедова Л.Н., Порханов В.А.Zyablova E.I., Nefedova L.N., Porkhanov V.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.oncoradjournal.ru/jour/article/view/130

В настоящее время иммунотерапия с успехом используются для лечения множественных злокачественных заболеваний, особенно на поздних стадиях метастазирования, которые до недавнего времени плохо поддавались лечению на основе стандартных протоколов. Положительные терапевтические эффекты иммунотерапии были продемонстрированы при лечении многих распространённых видов онкозаболеваний. Однако несмотря на выраженный положительный эффект у части пациентов, иммунотерапия может демонстрировать нетипичные формы ответа. Для постановки точного диагноза необходимо знать лучевые особенности иммунотерапевтических осложнений (irAE), в частности, таких как иммунотерапевтический пневмонит, колит, гипофизит, гепатит и миозит. Ранняя идентификация и соответствующее лечение irAE может улучшить исход пациента.

At present, immunotherapy is successfully used for the treatment of multiple malignant diseases, especially in the late stages of metastatic tumors, which until now, were difficult to treat using standards protocols. Positive therapeutic effects of immunotherapy were demonstrated in treatment of many common oncological diseases. However, despite the expressed positive effect, in some patients immunotherapy can demonstrate non-typical forms of the answer. To establish accurate diagnosis it is necessary to know radiological manifestations of immune-related adverse events (irAE), mainly, immune-mediated pneumonitis, colitis, hypophysitis, hepatitis and myositis. Early identification and the corresponding treatment of irAE may improve patient's outcomes.

онкологияиммунотерапияосложненияМРТКТoncologyimmunotherapyadverse eventrsCTMRIReferencesMichot JM, Bigenwald C, Champiat S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016;54:139-48. DOI: 10.1016/j.ejca.2015.11.016.Michot JM, Bigenwald C, Champiat S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016;54:139-48. DOI: 10.1016/j.ejca.2015.11.016.El Osta B, Hu F, Sadek R, et al. Not all immune-checkpoint inhibitors are created equal: Metaanalysis and systematic review of immune-related adverse events in cancer trials. Crit Rev Oncol Hematol. 2017;119:1-12. DOI: 10.1016/j.critrevonc.2017.09.002.El Osta B, Hu F, Sadek R, et al. Not all immune-checkpoint inhibitors are created equal: Metaanalysis and systematic review of immune-related adverse events in cancer trials. Crit Rev Oncol Hematol. 2017;119:1-12. DOI: 10.1016/j.critrevonc.2017.09.002.Nagai H, Muto M. Optimal management of immune-related adverse events resulting from treatment with immune checkpoint inhibitors: a review and update. Int J Clin Oncol. 2018;23:410-20. DOI: 10.1007/s10147-018-1259-6.Nagai H, Muto M. Optimal management of immune-related adverse events resulting from treatment with immune checkpoint inhibitors: a review and update. Int J Clin Oncol. 2018;23:410-20. DOI: 10.1007/s10147-018-1259-6.Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015;373:1627-39. DOI: 10.1056/NEJMoa1507643.Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015;373:1627-39. DOI: 10.1056/NEJMoa1507643.Wang GX, Kurra V, Gainor JF, et al. Immune Checkpoint Inhibitor Cancer Therapy: Spectrum of Imaging Findings. RadioGraphics. 2017;37:2132-44. DOI: 10.1148/rg.2017170085.Wang GX, Kurra V, Gainor JF, et al. Immune Checkpoint Inhibitor Cancer Therapy: Spectrum of Imaging Findings. RadioGraphics. 2017;37:2132-44. DOI: 10.1148/rg.2017170085.Tirumani SH, Ramaiya NH, Keraliya A, et al. Radiographic profiling of immune-related adverse events in advanced melanoma patients treated with ipilimumab. Cancer Immunol Res. 2015;3(10):1185-92. DOI: 10.1158/2326-6066.CIR-15-0102Tirumani SH, Ramaiya NH, Keraliya A, et al. Radiographic profiling of immune-related adverse events in advanced melanoma patients treated with ipilimumab. Cancer Immunol Res. 2015;3(10):1185-92. DOI: 10.1158/2326-6066.CIR-15-0102Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443-54. DOI:Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443-54. DOI:Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123-35. DOI: 10.1056/NEJMoa1504627Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123-35. DOI: 10.1056/NEJMoa1504627Vani V, Maglia C, Giannetto G, Pusceddu L, Timpani A, Doronzio VM, et al. Checkpoint inhibitor related adverse events: what the radiologist should be aware of. DOI: 10.26044/ecr2019/C-1319.Vani V, Maglia C, Giannetto G, Pusceddu L, Timpani A, Doronzio VM, et al. Checkpoint inhibitor related adverse events: what the radiologist should be aware of. DOI: 10.26044/ecr2019/C-1319.Faje AT, Sullivan R, Lawrence D, et al. Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J Clin Endocrinol Metab. 2014;99(11):4078-85. DOI: 10.1210/jc.2014-2306.Faje AT, Sullivan R, Lawrence D, et al. Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J Clin Endocrinol Metab. 2014;99(11):4078-85. DOI: 10.1210/jc.2014-2306.Carpenter KJ, Murtagh RD, Lilienfeld H, Weber J, Murtagh FR. Ipilimumab-induced hypophysitis: MR imaging findings. AJNR Am J Neuroradiol. 2009;30(9):1751-3. DOI: 10.3174/ajnr.A1623.Carpenter KJ, Murtagh RD, Lilienfeld H, Weber J, Murtagh FR. Ipilimumab-induced hypophysitis: MR imaging findings. AJNR Am J Neuroradiol. 2009;30(9):1751-3. DOI: 10.3174/ajnr.A1623.Calandri M, Solitro F, Angelino V, et al. The role of radiology in the evaluation of the immunotherapy efficacy. J Thorac Dis. 2018 May; 10(Suppl 13): S1438-S1446. DOI: 10.21037/jtd.2018.05.130.Calandri M, Solitro F, Angelino V, et al. The role of radiology in the evaluation of the immunotherapy efficacy. J Thorac Dis. 2018 May; 10(Suppl 13): S1438-S1446. DOI: 10.21037/jtd.2018.05.130.Nishino M, Ramaiya NH, Awad MM, et al. PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course. Clin Cancer Res. 2016;22:6051-60. DOI: 10.1158/1078-0432.CCR-16-1320.Nishino M, Ramaiya NH, Awad MM, et al. PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course. Clin Cancer Res. 2016;22:6051-60. DOI: 10.1158/1078-0432.CCR-16-1320.Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123-35. DOI: 10.1056/NEJMoa1504627.Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123-35. DOI: 10.1056/NEJMoa1504627.Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627-39. DOI: 10.1056/NEJMoa1507643.Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627-39. DOI: 10.1056/NEJMoa1507643.Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823-33. DOI: 10.1056/NEJMoa1606774.Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823-33. DOI: 10.1056/NEJMoa1606774.Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renalcell carcinoma. N Engl J Med. 2015;373(19):1803-13. DOI: 10.1056/NEJMoa1510665.Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renalcell carcinoma. N Engl J Med. 2015;373(19):1803-13. DOI: 10.1056/NEJMoa1510665.Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540-50. DOI: 10.1016/S0140-6736(15)01281-7.Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540-50. DOI: 10.1016/S0140-6736(15)01281-7.Nishino M, Ramaiya NH, Awad MM, et al. PD-1 inhibitor-related pneumonitis in advanced cancer patients: radiographic patterns and clinical course. Clin Cancer Res. 2016;22(24):6051-60. DOI: 10.1158/1078-0432.CCR-16-1320.Nishino M, Ramaiya NH, Awad MM, et al. PD-1 inhibitor-related pneumonitis in advanced cancer patients: radiographic patterns and clinical course. Clin Cancer Res. 2016;22(24):6051-60. DOI: 10.1158/1078-0432.CCR-16-1320.Delaunay M, Cadranel J, Lusque A, et al. Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients. Eur Respir J. 2017;50:1700050. DOI: 10.1183/13993003.000502017.Delaunay M, Cadranel J, Lusque A, et al. Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients. Eur Respir J. 2017;50:1700050. DOI: 10.1183/13993003.000502017.Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188(6):733-48. DOI: 10.1164/rccm.201308-1483ST.Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188(6):733-48. DOI: 10.1164/rccm.201308-1483ST.Tetzlaff MT, Nelson KC, Diab A, et al. Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients. J ImmunoTher Cancer. 2018;6:14. DOI: 10.1186/s40425-018-0323-0.Tetzlaff MT, Nelson KC, Diab A, et al. Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients. J ImmunoTher Cancer. 2018;6:14. DOI: 10.1186/s40425-018-0323-0.Tirumani SH, Ramaiya NH, Keraliya A, et al. Radiographic profiling of immune-related adverse events in advanced melanoma patients treated with ipilimumab. Cancer Immunol Res. 2015;3(10):1185-92. DOI: 10.1158/2326-6066.CIR-15-0102.Tirumani SH, Ramaiya NH, Keraliya A, et al. Radiographic profiling of immune-related adverse events in advanced melanoma patients treated with ipilimumab. Cancer Immunol Res. 2015;3(10):1185-92. DOI: 10.1158/2326-6066.CIR-15-0102.Braschi-Amirfarzan M, Tirumani SH, Hodi FS, et al. Immune-Checkpoint Inhibitors in the Era of Precision Medicine: What Radiologists Should Know. Korean J Radiol. 2017;18:42. DOI: 10.3348/kjr.2017.18.1.42.Braschi-Amirfarzan M, Tirumani SH, Hodi FS, et al. Immune-Checkpoint Inhibitors in the Era of Precision Medicine: What Radiologists Should Know. Korean J Radiol. 2017;18:42. DOI: 10.3348/kjr.2017.18.1.42.Gonzalez-Rodriguez E, Rodriguez-Abreu D. Spanish Group for Cancer Immuno-Biotherapy (GETICA). Immune check-point inhibitors: review and management of endocrine adverse events. Oncologist. 2016;21(7):804-16. DOI: 10.1634/theoncologist.2015-0509.Gonzalez-Rodriguez E, Rodriguez-Abreu D. Spanish Group for Cancer Immuno-Biotherapy (GETICA). Immune check-point inhibitors: review and management of endocrine adverse events. Oncologist. 2016;21(7):804-16. DOI: 10.1634/theoncologist.2015-0509.

The authors declare that there are no conflicts of interest present.